Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)
Others
Ratios

Bioadaptives (BDPT) EBT (2019 - 2025)

Historic EBT for Bioadaptives (BDPT) over the last 7 years, with Q3 2025 value amounting to -$379502.0.

  • Bioadaptives' EBT fell 90800.02% to -$379502.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$1.1 million, marking a year-over-year decrease of 16846.43%. This contributed to the annual value of -$694068.0 for FY2024, which is 7714.31% down from last year.
  • Per Bioadaptives' latest filing, its EBT stood at -$379502.0 for Q3 2025, which was down 90800.02% from -$157914.0 recorded in Q2 2025.
  • Over the past 5 years, Bioadaptives' EBT peaked at -$34516.0 during Q3 2021, and registered a low of -$491903.0 during Q1 2021.
  • Moreover, its 5-year median value for EBT was -$171151.0 (2022), whereas its average is -$204103.7.
  • As far as peak fluctuations go, Bioadaptives' EBT skyrocketed by 8092.29% in 2023, and later crashed by 90800.02% in 2025.
  • Bioadaptives' EBT (Quarter) stood at -$308336.0 in 2021, then skyrocketed by 62.1% to -$116851.0 in 2022, then grew by 13.79% to -$100734.0 in 2023, then plummeted by 244.51% to -$347036.0 in 2024, then dropped by 9.36% to -$379502.0 in 2025.
  • Its last three reported values are -$379502.0 in Q3 2025, -$157914.0 for Q2 2025, and -$258795.0 during Q1 2025.